Bulletin
Investor Alert

New York Markets Open in:

ZIOPHARM Oncology Inc.

NAS: ZIOP

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Dec 5, 2019, 6:07 p.m.

/zigman2/quotes/200291745/composite

$

5.15

Change

+0.06 +1.18%

Volume

Volume 6,444

Quotes are delayed by 20 min

/zigman2/quotes/200291745/composite

Previous close

$ 5.29

$ 5.09

Change

-0.20 -3.78%

Day low

Day high

$5.01

$5.35

Open

52 week low

52 week high

$1.56

$7.25

Open

Annual Financials for ZIOPHARM Oncology Inc.

Fiscal year is January-December. All values USD millions. 20142015201620172018 5-year trend
Sales/Revenue 1.37M4.33M6.86M6.39M146,000
Cost of Goods Sold (COGS) incl. D&A 462,000----
COGS excluding D&A -----
Depreciation & Amortization Expense 462,000357,000290,000369,000573,000
Depreciation 462,000357,000290,000369,000573,000
Amortization of Intangibles -----
Gross Income 911,000----
20142015201620172018 5-year trend
SG&A Expense 44.41M114.08M171.88M59.51M53.48M
Research & Development 32.71M96.79M157.79M45.08M34.13M
Other SG&A 11.7M17.29M14.09M14.43M19.35M
Other Operating Expense -----
Unusual Expense (11.72M)10M124,0001.3M(158,000)
EBIT after Unusual Expense (31.78M)(120.1M)(165.43M)(54.79M)(53.75M)
Non Operating Income/Expense (5,000)12,000134,000465,000631,000
Non-Operating Interest Income -----
Equity in Affiliates (Pretax) -----
Interest Expense -----
Gross Interest Expense -----
Interest Capitalized -----
Pretax Income (31.78M)(120.09M)(165.3M)(54.32M)(53.12M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (31.78M)(120.09M)(165.3M)(54.32M)(53.12M)
Minority Interest Expense -----
Net Income (31.78M)(120.09M)(165.3M)(54.32M)(53.12M)
Extraordinaries & Discontinued Operations ----207.36M
Extra Items & Gain/Loss Sale Of Assets ----207.36M
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (31.78M)(120.09M)(165.3M)(54.32M)154.24M
Preferred Dividends --7.12M18.94M17M
Net Income Available to Common (31.78M)(120.09M)(172.42M)(73.26M)(70.12M)
EPS (Basic) (0.31)(0.96)(1.32)(0.53)(0.49)
Basic Shares Outstanding 101.13M125.42M130.39M136.94M143.51M
EPS (Diluted) (0.31)(0.96)(1.32)(0.53)(0.49)
Diluted Shares Outstanding 101.13M125.42M130.39M136.94M143.51M
EBITDA (43.04M)(109.74M)(165.02M)(53.12M)(53.33M)
Link to MarketWatch's Slice.